爱美客：公司司美格鲁肽注射液适应症为体重管理，该项目目前在正常推进中

Group 1 - The core viewpoint of the article is that Aimeike (300896.SZ) is progressing normally with its project related to semaglutide for weight management, while the product from Yinnuo Pharmaceutical is aimed at glucose reduction [1] - Aimeike has been developing its semaglutide project for three years and has invested a significant amount of funds into it [3] - There is a concern regarding competition between Aimeike's semaglutide and Yinnuo Pharmaceutical's product, prompting questions about the company's strategic decisions in the current market environment [3]